NeoVentures Biotechnology Inc.

What NeoVentures Biotechnology Inc. does

NeoVentures Biotechnology Inc. is a Canadian private biotechnology company, founded in 2007 by CEO Dr. Gregory Penner and headquartered in London, Ontario, that develops custom aptamers and aptamer-based platforms for diagnostics, therapeutics, and drug discovery. The company's core technology is the proprietary Neomer selection method, which uses a reproducible library of 4.29 billion sequences with interspersed fixed and random nucleotides to enable single-round aptamer selection and in-silico immune tolerance screening against off-targets such as serum albumin, IgG, and mucins. NeoVentures operates an in-house laboratory equipped for Containment Level 2 work, cell culture, qPCR, SPRi, ITC, HPLC, and fluorometry, and complements Neomers with the FRELEX selection method for small-molecule targets and an Enzyme-Linked Oligonucleotide Assay (ELONA) diagnostic format. The company holds 85+ published patent applications and supports three primary product lines — Custom Aptamers (full-service development), In Silico Aptamers (library licensing at two price tiers), and Aptamarkers (biomarker discovery, operated through its Paris-based subsidiary NeoNeuro, co-founded in 2015).

The firm serves enterprise customers in three verticals: diagnostics companies (lateral flow, flow-through, biosensor, electrochemical, free-solution detection formats), therapeutics companies (targeted drug delivery, viral entry inhibition, endocytosis control), and drug discovery and development companies (high-throughput screening, lead compound selection, affinity purification). Customers receive global, irrevocable, exclusive, non-royalty bearing licenses to all generated aptamers. NeoVentures is founder-owned and bootstrapped, claiming financial stability without outside investment, and markets itself through content marketing (website, blog, case studies, publications), conference participation (e.g., BIO-Europe 2022), LinkedIn, YouTube, free feasibility consultations, and downloadable guides, with a sales-led direct engagement motion beginning with free project feasibility assessments before contract signature.

Name

NeoVentures Biotechnology Inc.

Legal name

NeoVentures Biotechnology Inc.

Website

https://neoaptamers.com

Company type

Private

Founded year

2007

Operating status

Operating

Short description

NeoVentures Biotechnology Inc. is a Canadian private biotech that develops custom aptamers and aptamer-based platforms using its proprietary Neomer selection method, serving enterprise customers in diagnostics, therapeutics, and drug discovery globally.

Ownership category

akta.pro rank

Product category

Aptamer Development Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Custom aptamer development
• Aptamer selection services
• Diagnostic aptamer development
• Therapeutic aptamer discovery
• Biomarker discovery platform

Headquarters

HQ city

London

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Custom Aptamer Development Services: Full-service aptamer development from project design through selection, validation, optimization, and regulatory support. Includes binding assays, truncation optimization, and signaling mechanism engineering. Clients receive global, irrevocable, exclusive, non-royalty bearing license to all developed aptamers.
2. In-Silico Aptamer Selection: Lower-cost option providing the Neomer library for client-performed selection, NGS frequency analysis, meta-analysis of structures, and candidate sequence selection. Two tiers: Option 1 includes library and analysis guidance; Option 2 adds NGS preparation.
3. Neomer Library Licensing: Licensing the Neomer library to labs with in-house selection capacity. Offers substantial savings over custom aptamer design while maintaining the same IP agreement with exclusive, non-royalty bearing, global, irrevocable license.
4. Aptamer Consulting Services: Expert consulting services for aptamer-related projects including feasibility assessments, strategy design, and product concept support through patent process, FDA approval, and CE mark.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

NeoVentures Biotechnology develops custom aptamers and aptamer-based platforms for diagnostics, therapeutics, and drug discovery applications. The company uses its proprietary Neomer selection method—a library of 4.29 billion reproducible sequences with in-silico immune tolerance screening—to deliver full-service custom aptamer development, including project design, selection execution, NGS analysis, validation, optimization, and regulatory support through patent, FDA, and CE mark processes.

Product overview

NeoVentures Biotechnology Inc. is an aptamer solutions provider offering a portfolio of products and services centered on its proprietary Neomers selection technology—a library of 4.29 billion reproducible sequences that enables single-round aptamer selection. The core offering is Custom Aptamers, a full-service development program encompassing project design, selection, validation, and optimization. Supporting products include In Silico Aptamers (licensing the Neomer library for in-house use), Aptamers for Multiple Targets (multi-epitope strategies), and Aptamer Validation services. The company also offers specialized platforms including Aptamarkers (biomarker discovery via subsidiary NeoNeuro) and FRELEX (small molecule selection). Diagnostic assay formats such as the Enzyme-Linked Oligonucleotide Assay (ELONA) extend commercial applications. NeoVentures operates a fully-equipped private laboratory and provides global, irrevocable, non-royalty bearing licenses to all developed aptamers.

Differentiator

Problem solved

Functional benefit

Brands

• Neomers: A novel aptamer selection method employing an expansive, reproducible library of 4.29 billion sequences that overcomes limitations of traditional SELEX selection.
• Aptamarkers
• FRELEX

Products and services

• Custom Aptamers Full-service custom aptamer development including project design, selection execution, NGS analysis, validation, optimization, and product concept support through patent and regulatory approval processes for biotech and pharmaceutical companies.
• In Silico Aptamers Licensing option allowing clients to use the Neomer library for in-house aptamer selection, offering cost savings with Option 1 (library plus analysis guidance) and Option 2 (library plus NGS preparation and sequencing services).
• Aptamers for Multiple Targets Selection strategy service for developing aptamers that bind to multiple targets or different epitopes on the same target, enabling applications such as sandwich assay formats for diagnostic and research customers.
• Aptamer Validation Validation service ensuring selected aptamers work for client product concepts, including binding assays in relevant commercial application formats such as lateral flow, flow-through, biosensors, electrochemical detection, and free solution detection.
• Aptamer Consulting Services Expert consultation services for aptamer development strategy, feasibility assessment, and product concept guidance through patent, FDA approval, and CE mark processes for clients evaluating aptamer-based approaches.
• Aptamarkers Biomarker discovery platform developed by the NeoNeuro subsidiary, enabling agnostic discovery of biomarkers for medical conditions and pharmacokinetic screening for drug development applications.
• Aptamer Discovery & Selection Core aptamer discovery service executing selection strategies, performing NGS analysis, and identifying candidate sequences against client-specified targets for biotech and pharmaceutical customers.

Quantifiable outcome

• Single-round selection capability reduces development time compared to traditional iterative SELEX
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

One partnership is on record.

• NeoNeurocoreOthersNeoNeuro is NeoVentures' French subsidiary based in Paris, co-founded in 2015 by Dr. Gregory Penner. Focused on innovative identification of Aptamarkers for complex diseases. Collaborates with NeoVentures parent company to develop and improve analytical pipelines for aptamer data analysis.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• AM Biotechnologies: Develops aptamers using proprietary technologies (including click chemistry-based approaches) for diagnostics and research. Comparable on the basis of offering novel aptamer selection methods to diagnostics and biotech customers.
• Base Pair Biotechnologies: US custom aptamer discovery and development CRO offering services across diagnostics, research, and therapeutics. Comparable to NeoVentures on custom aptamer development services and customer profile.
• Aptamer Group: UK-based custom aptamer selection and Optimer discovery services serving diagnostics, therapeutics, and research customers. Closely comparable to NeoVentures as a custom aptamer CRO with proprietary selection technology.
• SomaLogic (Standard BioTools): Operates the SomaScan aptamer-based proteomics platform for biomarker discovery and diagnostics, the most prominent commercial aptamer-discovery operation. Directly comparable to NeoVentures on core aptamer technology and on biomarker / diagnostic market focus.
• Aptagen: Custom aptamer development and isothermal amplification diagnostics specialist. Directly comparable to NeoVentures as a boutique aptamer services and reagent provider.

Broad incumbents

• Charles River Laboratories: Major CRO providing discovery and safety assessment services to pharma and biotech. Comparable as an enterprise-scale discovery CRO serving similar buyer personas, though not aptamer-specific.
• Eurofins Discovery: Global CRO offering a broad range of drug discovery services including custom assay/biologics capabilities. Comparable to NeoVentures as an enterprise-facing discovery services provider, though much larger and broader.
• Bio-Techne: Large life sciences tools company offering proteins, antibodies, and assay reagents. While not focused exclusively on aptamers, Bio-Techne competes broadly in affinity reagents and reagents for diagnostics/drug discovery.

Emerging players

• AptaBio: Aptamer therapeutics company focused on developing aptamer-based drugs. Comparable to NeoVentures' therapeutics applications and FRELEX method, but as a therapeutics developer rather than service provider.
• AbCellera: Antibody discovery platform using high-throughput screening and AI/ML for biologics discovery. Comparable as a tech-enabled biologics discovery platform serving pharma partners, though focused on antibodies rather than aptamers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCT48DpWUM87qO3bBIbq_ccA
• LinkedInlinkedin.com/company/5348393

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeoVentures Biotechnology Inc.